This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01478/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01478/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01478/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01478/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB01478/identifier/wikipedia/

Statements

Subject Item
n2:DB01478
rdf:type
n3:Drug
n3:description
Desmethylprodine, a derivative of meperidine, is an opioid analgesic with the potency of morphine. It has been listed as a Schedule I controlled drug in the United States, and thus is not used clinically. It is known to be a designer drug, synthesized in 1977, for the purpose of recreational use. Illicit manufacturing has occurred.
n3:generalReferences
1. Schmidt, N., and B. Ferger. "Neurochemical findings in the MPTP model of Parkinson's disease." Journal of neural transmission 108.11 (2001): 1263-1282.
n3:group
experimental illicit
owl:sameAs
n7:DB01478 n10:DB01478
dcterms:title
desmethylprodine
adms:identifier
n9:Desmethylprodine n11:DB01478 n12:61583 n13:55493 n14:46504635
n3:synonym
MPPP PPMP 3-Demethylprodine 1-Methyl-4-phenyl-4-propionoxypiperidine 1-Methyl-4-phenyl-4-piperidinol propionate
n3:toxicity
A toxic impurity which may be encountered in desmethylprodine synthesis, MPTP, is implicated in the destruction of brain tissue in the substantia nigra, and has lead to permanent Parkinsonian symptoms. [1]
n3:IUPAC-Name
n4:271B4E6C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E72-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E71-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E6E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E6F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E70-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E6A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4E68-363D-11E5-9242-09173F13E4C5 n4:271B4E6B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E69-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4E78-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E79-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E73-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E74-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E76-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E75-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E77-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
13147-09-6
n3:Bioavailability
n4:271B4E7D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E7F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E80-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E7C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E7B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E7E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E6D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E7A-363D-11E5-9242-09173F13E4C5